Related Experiment Video
Updated: May 19, 2026
10:37
Transcranial Direct Current Stimulation (tDCS) for Memory Enhancement
Published on: September 18, 2021
Could decitabine treatment impair memory functions in humans?
Burc Aydin1, Nil Hocaoglu, Sedef Gidener
1Department of Pharmacology, Dokuz Eylul University School of Medicine, Izmir, Turkey. burcaydin@gmail.com
Medical Hypotheses
|August 22, 2012
Summary
DNA methylation influences cognition. This study hypothesizes that decitabine, a DNA methyltransferase inhibitor used for myelodysplastic syndromes, may cause learning and memory deficits in patients, warranting clinical investigation.
Area of Science:
- Neuroscience
- Epigenetics
- Pharmacology
Background:
- Epigenetic mechanisms, particularly DNA methylation regulated by DNA methyltransferases (DNMTs), are increasingly recognized for their role in cognitive functions and neurological disorders.
- Decitabine (5-aza-2'-deoxycytidine) is a DNMT inhibitor used clinically for myelodysplastic syndromes (MDS).
- Preclinical studies suggest decitabine can negatively impact memory formation and consolidation.
Purpose of the Study:
- To investigate the potential for standard decitabine treatment in MDS patients without pre-existing dementia to induce learning and memory deficits.
- To explore the role of DNA methylation in human cognitive abilities through a clinical trial.
Main Methods:
- A clinical trial is proposed to evaluate cognitive function in MDS patients undergoing decitabine treatment.
- The study will assess learning and memory performance in participants.
Main Results:
- Hypothesized that decitabine treatment may lead to cognitive deficits in the studied patient population.
- Results are pending the proposed clinical trial.
Conclusions:
- The findings could establish a link between DNA methylation inhibition by decitabine and cognitive impairment in humans.
- This research may highlight the importance of monitoring cognitive function in patients receiving decitabine therapy.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:03Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Calcium Ion Concentration Mechanism
If over time, all...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:27CNS Depressants: Alcohol and Nicotine
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...